Neuropsychiatric events with varenicline: A modified prescription-event monitoring study in general practice in England

Drug Safety

Volumn 36, Issue 7, 2013, Pages 521-531

  Buggy, Yvonne ^a,b   Cornelius, Victoria ^c   Fogg, Carole ^a,b   Kasliwal, Rachna ^a,b   Layton, Deborah ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE;

ADULT; AGGRESSION; ANXIETY; ARTICLE; AUTOMUTILATION; COHORT ANALYSIS; DEPRESSION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL DISEASE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; SUICIDAL IDEATION; TOBACCO DEPENDENCE; UNITED KINGDOM;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; BENZAZEPINES; DRUG PRESCRIPTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENGLAND; FEMALE; GENERAL PRACTICE; HUMANS; INCIDENCE; MALE; MENTAL DISORDERS; MIDDLE AGED; NICOTINIC AGONISTS; PRODUCT SURVEILLANCE, POSTMARKETING; QUINOXALINES; SMOKING CESSATION;

EID: 84879947696     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0046-6     Document Type: Article

References (32)

1. Pfizer Ltd. Summary of product characteristics for Champix (Varenicline tartrate). Kent: Pfizer; 2006.
2. Tan L, Tang Q, Hao W. Nicotine dependence and smoking cessation. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009;34(11):1049-57.
3. Pfizer Ltd. Summary of product characteristics for Champix (Varenicline tartrate). Kent: Pfizer; 2009.
4. Natividad LA, Tejeda HA, Torres OV, O'Dell LE. Nicotine withdrawal produces a decrease in extracellular levels of dopamine in the nucleus accumbens that is lower in adolescent versus adult male rats. Synapse. 2009;64(2):136-45.
5. Medicines and Healthcare products Regulatory Agency (MHRA). Varenicline: suicidal thoughts and behaviour. London: MHRA; 2008.
6. US FDA. Public health advisory: important information of Champix. Silver Spring: US FDA; 2008.
7. Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf. 2010;33(4):289-301.
8. Harrison-Woolrych M, Ashton J. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug Saf. 2011;34(9):763-72.
9. Shakir SA. PEM in the UK. In: Mann RD, Andrews EB, editors. Pharmacovigilance. Chichester: Wiley; 2007. p. 307-16.
10. Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. Drug Saf. 2011;34(12):e1-9.
11. CIOMS. International guidelines for biomedical research involving human subjects. Geneva: CIOMS; 2002.
12. Cornelius VR, Evans SJW. The use of time to event models in signal detection. Drug Saf. 2009;32(10):926.
13. Cornelius VR, Sauzet O, Evans SJW. A signal detection method for adverse drug reaction using a parametric time to event model for longitudinal cohort data. Drug Saf. 2012;35(7):599-610.
14. Jimenez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. Drugs. 2009;69(10):1319-38.
15. McClure JB, Swan GE, Jack L, Catz SL, Zbikowski SM, McAfee TA, et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med. 2009;24(5):563-9.
16. Farrell M, Howes S, Bebbington P, Brugha T, Jenkins R, Lewis G, et al. Nicotine, alcohol and drug dependence, and psychiatric comorbidity: results of a national household survey. Int Rev Psychiatry. 2003;15(1-2):50-6.
17. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.
18. Kessler RC, Borges G, Sampson N, Miller M, Nock MK. The association between smoking and subsequent suicide-related outcomes in the National Comorbidity Survey panel sample. Mol Psychiatry. 2009;14(12):1132-42.
19. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLoS One. 2011;6(11):e27016.
20. McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, et al. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf. 2010;33(9):775-88.
21. Grover KW, Goodwin RD, Zvolensky MJ. Does current versus former smoking play a role in the relationship between anxiety and mood disorders and nicotine dependence? Addict Behav. 2012;37(5):682-5.
22. Bolam B, West R, Gunnell D. Does smoking cessation cause depression and anxiety? Findings from the ATTEMPT cohort. Nicotine Tob Res. 2011;13(3):209-14.
23. Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports of violence towards others. PLoS One. 2010;5(12):e15337.
24. Rouve N, Bagheri H, Telmon N, Pathak A, Franchitto N, Schmitt L, et al. Prescribed drugs and violence: a case/noncase study in the French PharmacoVigilance Database. Eur J Clin Pharmacol. 2011;67(11):1189-98.
25. Moore TJ, Glenmullen J, Furberg CD. Thoughts and acts of aggression/violence toward others reported in association with varenicline. Ann Pharmacother. 2010;44(9):1389-94.
26. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
27. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561-8.
28. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007;29(6):1027-39.
29. McAvoy BR, Kaner EF. General practice postal surveys: a questionnaire too far? BMJ. 1996;313(7059):732-3. discussion 3-4.
30. Office for National Statistics. Migration statistics 2008 annual report. Office of National Statistics, 2008. http://www.ons.gov.uk/ons/search/index. html?newquery=%22Migration+statistics+annual+report%22+2008. Accessed 3 Mar 2013.
31. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf. 2009;32(5):409-18.
32. Pfizer Ltd. Summary of product characteristics for Champix (Varenicline tartrate). Kent: Pfizer; 2008.